Neuralstem Inc.

Neuralstem Inc. is focused on developing and commercializing treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. The company has developed and maintains a portfolio of patents and patent applications that form the base of its research and development efforts in neural stem cell research, small molecule research and related technologies. Neuralstem has also developed and patented a series of small molecule compounds (low molecular weight organic compounds) that can efficiently cross the blood/brain barrier.

Expert Comments:

John Peabody, Seeking Alpha (3/18/15)
"Neuralstem Inc. recently disclosed strong topline amyotrophic lateral sclerosis Phase 2 study results from an open-label, nonplacebo-controlled human clinical trial of NSI-566. In addition to meeting the primary safety endpoints, the preliminary topline results for secondary efficacy endpoints indicated there was a 47% response rate (seven of 15 patients responded) to the treatment with NSI-566."

Robert Stuart, Seeking Alpha (3/17/15)
"Recently released data from Neuralstem Inc.'s Phase 2 trial in Lou Gehrig's disease has brought on panic selling, but a patient investor may profit from impatient investors. . .it remains to be seen whether NSI-566 has given more time to patients with amyotrophic lateral sclerosis or not, but it is certainly too soon to dismiss the potential of the treatment."

Sirius Capital, Seeking Alpha (3/17/15)
"We were very excited last week when Neuralstem Inc. announced the topline results of its Phase 2 amyotrophic lateral sclerosis trial. In the study, it found that the treatment was effective in virtually stopping the progression of the disease in almost half of the subjects (seven of the 15 participants, 47%). . .we believe that the successful results of this study and the intention of the company to begin shortly with more studies provide major derisking for the treatment."

Reni Benjamin, H.C. Wainwright & Co. (3/17/15)
"Neuralstem Inc. reported topline results from a 15-patient, Phase 2 trial of NSI-566 in amyotrophic lateral sclerosis, demonstrating that a subset of patients may benefit from the cell therapy. . .the company plans to initiate a Phase 2 trial of NSI-189 for major depressive disorder in Q2/15 and a Phase 1b trial in schizophrenia-related cognitive deficit in mid-2015."

Larry Smith, SmithOnStocks (3/16/15)
"I have a high level of confidence that the efficacy results seen in Neuralstem Inc.'s Phase 1 and 2 trials indicate that the surgically implanted NSI-566 neural stem cells result in a clinically important outcome in some percentage of amyotrophic lateral sclerosis patients. . .I continue with my Buy recommendation on the stock."

Larry Smith, SmithOnStocks (3/10/15)
"Neuralstem Inc.'s management has guided that the Phase 2 data on 15 patients treated in the Phase 2 trial of NSI-566 neural stem cells in the treatment of amyotrophic lateral sclerosis will be released in Q1/15. . .there will almost certainly be some patients who do not do well, but on balance it should be an encouraging report, and I expect that the company will use this as a basis to talk with the U.S. Food and Drug Administration about a pivotal Phase 3 trial."

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Neuralstem Inc. Content